Moore Kuehn Encourages SFTW, PRAH, RTP, and PAND Investors to Contact Law Firm
26 févr. 2021 10h49 HE
|
Moore Kuehn
NEW YORK, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims...
Pandion Therapeutics to Present at the 10th Annual SVB Leerink Global Healthcare Conference
18 févr. 2021 08h30 HE
|
Pandion Therapeutics, Inc.
WATERTOWN, Mass., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
Pandion Therapeutics Highlights Potential of Modular Biologics Pipeline for the Treatment of Autoimmune Diseases at FOCIS 2020
28 oct. 2020 08h00 HE
|
Pandion Therapeutics, Inc.
WATERTOWN, Mass., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
Pandion Therapeutics to Participate in Panel Discussion at Stifel 2020 Immunology & Inflammation Virtual Summit
24 sept. 2020 08h00 HE
|
Pandion Therapeutics, Inc.
WATERTOWN, Mass., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...
Pandion Reports Second Quarter 2020 Financial Results and Provides Business Update
31 août 2020 16h05 HE
|
Pandion Therapeutics, Inc.
- Completed successful IPO providing approximately $153 million in gross proceeds; cash runway extended through first half of 2024 - Expanded executive team with appointment of John S. Sundy, M.D.,...
Pandion Therapeutics Announces Pricing of Initial Public Offering
16 juil. 2020 21h01 HE
|
Pandion Therapeutics, Inc.
WATERTOWN, Mass., July 16, 2020 (GLOBE NEWSWIRE) -- Pandion Therapeutics, Inc. (Nasdaq: PAND), a clinical-stage biotechnology company developing novel therapeutics designed to address the unmet...